 Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
- Chemotherapeutic Anticancer Drug
- Drug, Chemotherapeutic Anticancer
- Antitumor Drugs
- Drugs, Antitumor
- Cancer Chemotherapy Agents
- Agents, Cancer Chemotherapy
- Chemotherapy Agents, Cancer
- Cancer Chemotherapy Drugs
- Chemotherapy Drugs, Cancer
- Drugs, Cancer Chemotherapy
- Chemotherapeutic Anticancer Agents
- Agents, Chemotherapeutic Anticancer
- Anticancer Agents
- Agents, Anticancer
- Antitumor Agents
- Agents, Antitumor
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 1 | 6 | | 1997 | 4 | 4 | 8 | | 1998 | 10 | 4 | 14 | | 1999 | 12 | 5 | 17 | | 2000 | 8 | 5 | 13 | | 2001 | 5 | 7 | 12 | | 2002 | 19 | 7 | 26 | | 2003 | 17 | 10 | 27 | | 2004 | 21 | 10 | 31 | | 2005 | 22 | 10 | 32 | | 2006 | 33 | 8 | 41 | | 2007 | 47 | 14 | 61 | | 2008 | 40 | 17 | 57 | | 2009 | 40 | 25 | 65 | | 2010 | 46 | 17 | 63 | | 2011 | 51 | 18 | 69 | | 2012 | 46 | 29 | 75 | | 2013 | 56 | 28 | 84 | | 2014 | 57 | 23 | 80 | | 2015 | 62 | 28 | 90 | | 2016 | 73 | 42 | 115 | | 2017 | 62 | 30 | 92 | | 2018 | 66 | 22 | 88 | | 2019 | 47 | 19 | 66 | | 2020 | 45 | 11 | 56 | | 2021 | 37 | 3 | 40 | | 2022 | 30 | 4 | 34 | | 2023 | 34 | 1 | 35 | | 2024 | 23 | 26 | 49 | | 2025 | 43 | 7 | 50 | | 2026 | 15 | 1 | 16 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Fontebasso AM, Rytlewski JD, Blay JY, Gladdy RA, Wilky BA. Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors. Hematol Oncol Clin North Am. 2026 10; 40(5):875-894.
-
Chen S, Repp ML, Teran S, Kondapalli L. Female Cardiovascular Health After Childhood Cancer. Curr Cardiol Rep. 2026 Sep 18; 28(1).
-
Oswald LB, Hoogland AI, Welniak TL, Nguyen OL, Rodriguez Y, Li X, Reese S, Lake PW, Gonzalez BD, Extermann M, Metts J, Murphy MA, Small BJ, Berry DL, Li D, Carpenter KM, Fischer SM, Kinney AY, Jim HSL. Comparing chemotherapy-induced nausea and vomiting between young adult vs non-young adult cancer patients. JNCI Cancer Spectr. 2026 Sep 03; 10(5).
-
Cole AR, Buj R, Uboveja A, Levasseur E, Tom A, Wang H, Kedziora KM, Chatoff A, Huacachino AA, Marcinkiewicz MM, Amalric A, Yang B, Tangudu NK, Noonan E, Danielson J, Naruse M, Elhaw AT, White S, Li D, Wallace CT, Keeney F, Lazure F, Elishaev E, Borho L, Townsend HA, Dowell RD, Clauset A, Jazwinska DE, Laird MS, Atiya H, Dangaj D, Coffman LG, Tseng G, Oesterreich S, Kossenkov A, Liu Q, Gomes AP, Gurkar AU, Schopfer FJ, Modugno F, Watkins SC, Zervantonakis IK, Bitler BG, Stallaert W, Hempel N, Snyder NW, Aird KM. The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming. Nat Aging. 2026 Aug; 6(8):1647-1666.
-
Phillips WJ, Leong R, Yeung B, Al Lawati A, Camidge DR, Lo B, Wheatley-Price P. The Prognostic Significance of EGFR Adjusted Variant Allele Frequency on First-Line Osimertinib Efficacy in Advanced EGFR-Mutant NSCLC. Curr Oncol. 2026 Jul 23; 33(8).
-
Padilla MS, Li JJ, Zhang Q, Patwari K, Shi S, Yamagata HM, Joseph RA, Hymms BN, Teerdhala SV, Fitzgerald E, Chalom OZ, Gupta K, Alameh MG, Weissman D, Le AD, Mitchell MJ. Lipid Nanoparticle Co-Delivery of mRNA and a Small Molecule Drug for Oral Cancer Chemoimmunotherapy. Adv Mater. 2026 Aug; 38(47):e73721.
-
Barac A, Guha A, Fleming TR, Bonaca M, Thavendiranathan P, Deswal A, Amiri-Kordestani L, Bhatnagar V, Cordoba R, Hurvitz S, Adjei AA, Agarwal N. Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. Circulation. 2026 Aug 04; 154(5):e188-e205.
-
Barac A, Guha A, Fleming TR, Bonaca M, Thavendiranathan P, Deswal A, Amiri-Kordestani L, Bhatnagar V, Cordoba R, Hurvitz S, Adjei AA, Agarwal N. Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. J Clin Oncol. 2026 Aug; 44(22):2140-2155.
-
Zhou C, Greillier L, Liu G, John T, Xing L, Kowalski D, Memmott RM, Yazici O, Sun M, Shu CA, Pons-Tostivint E, Fan Y, Fernandez-Hinojal G, Shum E, Wang M, Bertolini F, Camidge DR, Zhou C, Doucet L, Hong Q, Fang J, Huang D, Jin B, Yu Y, Antonuzzo L, Moro-Sibilot D, Bennouna J, de Castro G, Zheng L, Heymach JV. First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. N Engl J Med. 2026 Aug 20; 395(8):765-775.
-
Knudsen ES, Witkiewicz AK, Kabraji S. The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond. Nat Rev Drug Discov. 2026 Jul; 25(7):516-533.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|